Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Blood (2019) 134 (Supplement_1): 921.

https://doi.org/10.1182/blood-2019-127399

Published: 2019

Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD

Blood (2019) 134 (Supplement_1): 884.

https://doi.org/10.1182/blood-2019-132057

Published: 2019

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Sang Eun Yoon, Won Seog Kim, MD PhD, Seok Jin Kim, MD PhD, Young Hyeh Ko, MD, Kim Yeon Jeong, PhD, Park Donghyun, PhD

Blood (2019) 134 (Supplement_1): 1491.

https://doi.org/10.1182/blood-2019-130075

Published: 2019

Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD

Blood (2019) 134 (Supplement_1): 1581.

https://doi.org/10.1182/blood-2019-128475

Published: 2019

Journal Articles

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Carlyn Rose Tan, MD, Stefan K. Barta, MD MRCP, MS, Shelly Y. Lensing, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1595.

https://doi.org/10.1182/blood-2019-129702

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Mohammad Shahrokh Esfahani, Stefan Alig, MD, David M. Kurtz, MD PhD, Joanne Soo, MD, Michael C. Jin, BS, Charles Macaulay, MSc, BA, Alexander F. M. Craig, MPhil, Andrea Garofalo, BS, BA, Chloe B. Steen, MSc, Florian Scherer, MD, Brian Sworder, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 551.

https://doi.org/10.1182/blood-2019-132069

Published: 2019

Journal Articles

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

David M. Kurtz, MD PhD, Joanne Soo, MD, Stefan Alig, MD, Lyron Co Ting Keh, Charles Macaulay, Michael C. Jin, BS, Florian Scherer, MD, Emily G. Hamilton, BS, Chih Long Liu, PhD, Binbin Chen, PhD, Alexander F. M. Craig, MPhil, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 552.

https://doi.org/10.1182/blood-2019-131267

Published: 2019

Journal Articles

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Brian Sworder, MD PhD, David M. Kurtz, MD PhD, Charles Macaulay, MSc, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, Andrea Garofalo, BS, BA, Bita Sahaf, PhD, Mohammad Shahrokh Esfahani, Jay Y. Spiegel, MDFRCPC, Jean Oak, MD PhD, Sara Beygi, MD, Michael C. Jin, BS, Jacob J Chabon, Michael S. Khodadoust, MD PhD, Robbie G. Majzner, MD, Crystal L. Mackall, MD, Maximilian Diehn, MD PhD, David B Miklos, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 550.

https://doi.org/10.1182/blood-2019-129015

Published: 2019

Journal Articles

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

Ehsan Tabari, PhD, Alexander F Lovejoy, PhD, Hai Lin, PhD, Christopher R Bolen, PhD, Seng Lor Saelee, BA, Joshua P Lefkowitz, David M. Kurtz, MD PhD, Patrik Vitazka, MD PhD, Jeffrey M. Venstrom, MD PhD, Tina G Nielsen, MD PhD, Joana M Parreira, MD, Daniel M Klass, PhD, Khai T Luong, PhD

Blood (2019) 134 (Supplement_1): 490.

https://doi.org/10.1182/blood-2019-123633

Published: 2019

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 2877.

https://doi.org/10.1182/blood-2019-128021

Published: 2019

Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5299.

https://doi.org/10.1182/blood-2019-124997

Published: 2019

Journal Articles

Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes

Mariana Bastos-Oreiro, MD PhD, Julia Suárez González, Natalia Carolina Carrión, Cristina Andres, Solsireey Moreno, Diego Carbonell, Mr, María Chicano Lavilla, PhD, Gillen Oarbeascoa, MD, Francisco Diaz Crespo, Javier Menarguez, MD PhD, José Luis Díez-Martín, MD PhD, Ismael Buño, PhD, Carolina Martínez-Laperche

Blood (2019) 134 (Supplement_1): 5216.

https://doi.org/10.1182/blood-2019-129868

Published: 2019

Journal Articles

Genomic Analysis of Therapy-Related Myeloid Neoplasms and Tracking of the Founder Clone By Circulating Tumor DNA

Kanya Kondoh, MD, Kazuaki Yokoyama, MD PhD, Nozomi Yusa, Mika Ito, Eigo Shimizu, Sousuke Nakamura, MD, Miho Ogawa, MD, Tomomi Takei, MD, Asako Kobayashi, Rika Kasajima, PhD, Yuka Wada, Rui Yamaguchi, PhD, Seiya Imoto, PhD, Tokiko Nagamura-Inoue, MD PhD, Kaoru Uchimaru, MD, PhD, Satoru Miyano, PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 5393.

https://doi.org/10.1182/blood-2019-127611

Published: 2019

Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 1885.

https://doi.org/10.1182/blood-2019-125383

Published: 2019

Journal Articles

Trasposon Mediated Horizontal Gene Transfer (T-HGT) of Circulating Tumor DNA Reshapes MM Clonal Architecture

Munevver Cinar, MD, Steven Flygare, Marina Mosunjac, Ganji Nagaraju, Dongkyoo Park, Sheff Faith, Debra Saxe, PhD, Leon Bernal-Mizrachi, MD

Blood (2019) 134 (Supplement_1): 3065.

https://doi.org/10.1182/blood-2019-126699

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes

Genomic Analysis of Therapy-Related Myeloid Neoplasms and Tracking of the Founder Clone By Circulating Tumor DNA

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

Trasposon Mediated Horizontal Gene Transfer (T-HGT) of Circulating Tumor DNA Reshapes MM Clonal Architecture

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only